RET rearrangement

P=N/A, N=85, Not yet recruiting, University of Calgary

We further discuss emerging therapeutic strategies targeting glucose metabolism and highlight challenges including isoform-specific regulation and biomarker-driven patient stratification. This review provides a conceptual framework for translating metabolic insights into improved diagnosis and therapy for TC.

The present study postulates that some of the major nutritional factors can be significantly associated with thyroid carcinogenesis. While the RET/PTC rearrangements are the prime concern in thyroid cancer in the Pakistani population. The higher expression of RET/PTC1 and RET/PTC3 identified in thyroid cancer patients presents the potential target to be down regulated customized molecular therapies.

This case highlights the importance of an integrated morphologic, immunophenotypic, and molecular diagnostic approach in atypical spitzoid lesions. Identification of an isolated RET fusion supports classification within the Spitz tumor spectrum and provides valuable information for risk stratification and clinical management in pediatric patients.

We present a case of a 66-year-old female with de novo metastatic NSCLC harboring an EGFR mutation, RET rearrangement, and ERBB2 amplification, who experienced transformation to SCLC while on osimertinib. Subsequently, she exhibited primary refractory disease to both first-line platinum doublet with immunotherapy and second-line lurbinectedin...The patient had minimal side effects and obtained a partial response with a progression-free survival (PFS) of 13.1 months, better than historically poor prognosis seen in transformed SCLC. This case underscores the potential role of human epidermal growth factor receptor 2 (HER-2) directed therapies, such as T-DXd, in transformed SCLC.

A high proportion of inconclusive results was observed, likely reflecting technical limitations related to the use of formalin-fixed, paraffin-embedded tissue. In conclusion, RET fusions were relatively uncommon in this Brazilian cohort but were enriched in younger patients, underscoring age-related differences in the molecular landscape of pediatric thyroid carcinoma and highlighting the need for larger, standardized multicenter studies.

This study suggests that pathologic prescreening can enrich for targetable gene rearrangements in BRAF wild-type PTC and serve as a resource-sparing strategy before RNA sequencing. In prescreened cases, ALK IHC performed well, while pan-TRK and RET IHC had limitations.

GGOs exhibit a distinct genomic and PD-L1 profile with significant age-related heterogeneity, providing insights for age-stratified therapeutic strategies.

P2, N=125, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P1/2, N=456, Recruiting, Sunshine Lake Pharma Co., Ltd. | Trial primary completion date: Jul 2025 --> Dec 2026

Treatment and prognosis: Following diagnosis, the child was administered rapamycin-targeted therapy in conjunction with compound sulfamethoxazole to prevent infections, with regular monitoring of rapamycin blood concentrations. Subsequent follow-up indicated a significant reduction in the frequency of pulmonary infection episodes, a decrease in the size of the enlarged lymph nodes in the neck, and effective control of the condition.

Stage III ALK-positive NSCLC is prone to relapse but local therapy combined with adjuvant ALK TKIs offers a promising strategy. Patients with EML4-ALK v1 mutations may show improved outcomes.